GENTAUR Belgium BVBA BE0473327336 Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc,Logistics 547 Yurok Circle, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, [email protected]

Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, Gentaur another in time delivery

Pubmed ID: 33924378
Publication Date: 2021/04/13

Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.


AMHRII, the anti-Müllerian hormone receptor, is selectively expressed in normal sexual organs but is also re-expressed in gynecologic cancers. Hence, we developed murlentamab, a humanized glyco-engineered anti-AMHRII monoclonal antibody currently in clinical trial. Low-fucosylated antibodies are known to increase the antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) potency of effector cells, but some preliminary results suggest a more global murlentamab-dependent activation of the immune system. In this context, we demonstrate here that the murlentamab opsonization of AMHRII-expressing ovarian tumor cells, in the presence of unstimulated- or tumor-associated macrophage (TAM)-like macrophages, significantly promotes macrophage-mediated ADCC and shifts the whole microenvironment towards a pro-inflammatory and anti-tumoral status, thus triggering anti-tumor activity. We also report that murlentamab orients both unstimulated- and TAM-like macrophages to an M1-like phenotype characterized by a strong expression of co-stimulation markers, pro-inflammatory cytokines and chemokines, favoring T cell recruitment and activation. Moreover, we show that murlentamab treatment shifts CD4 Th1/Th2 balance towards a Th1 response and activates CD8 T cells. Altogether, these results suggest that murlentamab, through naïve macrophage orientation and TAM reprogrammation, stimulates the anti-tumor adaptive immune response. Those mechanisms might contribute to the sustained clinical benefit observed in advanced cancer patients treated with murlentamab. Finally, the enhanced murlentamab activity in combination with pembrolizumab opens new therapeutic perspectives.
Authors: Prat Mélissa , Salon Marie , Allain Thibault , Dubreuil Olivier , Noël Grégory , Preisser Laurence , Jean Bérangère , Cassard Lydie , Lemée Fanny , Tabah-Fish Isabelle , Pipy Bernard , Jeannin Pascale , Prost Jean-François , Barret Jean-Marc , Coste Agnès ,

Reference:

  1. ncbi.nlm.nih.gov. [Last access 2021/04/13].

Related products :

Catalog number Product name Quantity
20-783-72870 MOUSE ANTI HUMAN TNF RECEPTOR 2 - Tumor necrosis factor receptor 2; TNF-R2; Tumor necrosis factor receptor type II; p75; p80 TNF-alpha receptor; CD120b antigen; Etanercept Monoclonal 0.1 mg
E12410406 Rat B Cell Activation Factorr From The Tumor Necrosis Factor Family Receptor(BAFF-R)ELISA Kit 1
SL0323Hu Human B cell activation factorr from the tumor necrosis factor family receptor,BAFF-R ELISA Kit 96T
201-12-0269 Human B cell activation factorr from the tumor necrosis factor family receptor,BAFF-R ELISA Kit 48T
E12530315 Mouse B Cell Activation Factorr From The Tumor Necrosis Factor Family Receptor(BAFF-R)ELISA Kit 1